We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
The latest trading session saw Bristol Myers Squibb (BMY - Free Report) ending at $49.80, denoting a -0.32% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.3%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, added 0.25%.
The biopharmaceutical company's stock has climbed by 7.44% in the past month, exceeding the Medical sector's gain of 4.56% and the S&P 500's gain of 3.42%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company's earnings per share (EPS) are projected to be $1.58, reflecting a 21% decrease from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $11.29 billion, up 2.97% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.77 per share and revenue of $46.82 billion, which would represent changes of -89.75% and +4.04%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.2% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 64.74. This represents a premium compared to its industry's average Forward P/E of 23.2.
Meanwhile, BMY's PEG ratio is currently 12.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.15 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 84, putting it in the top 34% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
The latest trading session saw Bristol Myers Squibb (BMY - Free Report) ending at $49.80, denoting a -0.32% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.3%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, added 0.25%.
The biopharmaceutical company's stock has climbed by 7.44% in the past month, exceeding the Medical sector's gain of 4.56% and the S&P 500's gain of 3.42%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company's earnings per share (EPS) are projected to be $1.58, reflecting a 21% decrease from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $11.29 billion, up 2.97% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.77 per share and revenue of $46.82 billion, which would represent changes of -89.75% and +4.04%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.2% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 64.74. This represents a premium compared to its industry's average Forward P/E of 23.2.
Meanwhile, BMY's PEG ratio is currently 12.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.15 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 84, putting it in the top 34% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.